TNFα 阻断在免疫检查点抑制剂治疗中的作用：利大于弊，还是弊大于利？
TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?
机构信息
Laura and Isaac Perlmutter Comprehensive Cancer Center at NYU Langone Health, New York, New York.
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
出版信息
Clin Cancer Res. 2020 May 1;26(9):2085-2086. doi: 10.1158/1078-0432.CCR-20-0387. Epub 2020 Feb 26.
The impact on survival of steroids and TNFα blockade to treat immune-related toxicity from checkpoint blockade with ipilimumab, nivolumab/pembrolizumab, or combined ipilimumab and nivolumab was assessed using data from a large national database. Using steroids was associated with better survival than the use of TNFα-blocking antibodies such as infliximab..
使用大型国家数据库的数据评估了使用类固醇和 TNFα 阻断剂治疗伊匹单抗、纳武利尤单抗/帕博利珠单抗或伊匹单抗联合纳武利尤单抗的检查点阻断相关免疫相关毒性的生存影响。与使用英夫利昔单抗等 TNFα 阻断抗体相比，使用类固醇与更好的生存相关。
Zotero 插件